Slowing Parkinson's Disease Progression
Neurol 60:381-389, Ahlskog,J.E., 2003

Initial Agonist Treatment of Parkinson Disease
Neurol 60:390-394, Albin,R.L. &Frey,K.A., 2003

Clinicopath Conf., Penumococcal penumonia with Endocarditis and Endophtlhalmitis
NEJM 348:834-842, Case 7-2003, 2003

[123I]b-CIT SPECT is a Useful Method for Monitoring Dopaminergic Degeneration in Early Stage Parkinson's Disease
JNNP 74:294-298,287, Winogrodzka,A.,et al, 2003

Ten Most Commonly Asked Questions About the Psychiatric Aspects of Parkinson's Disease
The Neurologist 9:50-56, Reich,S.G. & Marsh,L., 2003

Neuronal Loss Is Greater in the Locus Coeruleus Than Nucleus Basalis and Substantia Nigra in Alzheimer and Parkinson Diseases
Arch Neurol 60:337-341, 320, Zarow,C.,et al, 2003

Clinical Features and Natural Histry of Progressive Supranuclear Palsy, A Clinical Cohort Study
Neurol 60:910-916, Nath,W.,et al, 2003

Diffusion-Weighted Imaging Discriminates Progressive Supranuclear Palsy from PD, But Not From the Parkinson Variant of Multiple System Atrophy
Neurol 60:922-927, Seppi,K.,et al, 2003

Stem Cells and Neurological Disease
JNNP 74:553-557, Barker,R.A.,et al, 2003

Randomized Trial of Pallidotomy Versus Medical Therapy for Parkinson's Disease
Ann Neurol 53:558-569, Vitek,J.L.,et al, 2003

Weight Loss in Parkinson's Disease
Ann Neurol 53:676-679, Chen,H.,et al, 2003

Parkinson Disease With Old-Age Onset
Arch Neurol 60:529-533, Diederich,N.J.,et al, 2003

Identifying the Pattern of Olfactory Deficits in Parkinson Disease Using the Brief Smell Identification Test
Arch Neurol 60:545-549, Double,K.L.,et al, 2003

Alzheimer's Disease and Parkinson's Disease
NEJM 348:1356-1364, Nussbaum,R.L. &Ellis,C.E., 2003

Acupuncture in Clinical Neurology
The Neurologist 9:137-148, Rabinstein,A.A. &Shulman,L.M., 2003

Kennedy Disease
Arch Neurol 60:893-894, Paparounas,K.,et al, 2003

Bilateral Subthalamic Nucleus Stimulation Improves Health-Related Quality of Life in PD
Neurol 59:1976-1978, Lagrange,E.,et al, 2002

Treatment Interventions for Parkinson's Disease: An Evidence Based Assessment
Lancet 359:1589-1598, Rascol,O.,et al, 2002

New Strategy for Prenatal Diagnosis of X-Linked Disorders
NEJM 346:1502, Costa,J.,et al, 2002

Impact of Sustained Deprenyl (Selegiline) in Levodopa-Treated Parkinson's Disease: A Randomized Placebo-Controlled Extension of the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism Trial
Ann Nuerol 51:604-612, Shoulson,I.,et al, 2002

Cholinergic Vesicular Transporters in Progressive Supranuclesar Palsy
Neurol 58:1013-1018,997, Suzuki,M.,et al, 2002

Botulinum Toxin for Cricopharyngeal Dysfunction in Parkinson's Disease
NEJM 346:1174-1175, Restivo,D.A.,et al, 2002

How Valid is the Clinical Diagnosis of Parkinson's Disease in the Community?
JNNP 73:529-534, Scharg,A.,et al, 2002

Jaw Drop in Kennedy's Disease
Neurol 59:1471-1472, Sumner,C.J. &Fischbeck,K.H., 2002

Blepharospasm
Neurol 59:1306-1312, Hallett,M., 2002

Ptosis as a Remote Effect of Therapeutic Botulinum Toxin B Injection
Neurol 59:1445-1447, Racette,B.A.,et al, 2002

Effect on Mood of Subthalamic DBS for Parkinson's Disease
Neurol 59:1427-1429, Berney,A.,et al, 2002

Mania Following Deep Brain Stimulation for Parkinson's Disease
Neurol 59:1421-1424, Kulisevsky,J.,et al, 2002

Posterior Circulation Stroke in Childhood
Neurol 59:1552-1556, Ganesan,V.,et al, 2002

Diagnostic Criteria for Dystonia in DYT1 Families
Neurol 59:1780-1782, Bressman,S.B.,et al, 2002

Driving Safety in Parkinson's Disease
Neurol 59:1787-1788, Zesiewicz,T.A.,et al, 2002

Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
JAMA 287:1653-1661, Parkinson Study Group, 2002

Nonmotor Fluctuations in Parkinson's Disease
Neurol 59:408-413, Witjas,T.,et al, 2002

Reversible Chorea and Focal Dystonia in Vitamin B12 Deficiency
NEJM 347:295, Pacchetti,C.,et al, 2002

A Meta-Analysis of Coffee Drinking, Cigarette Smoking, and the Risk of Parkinson's Disease
Ann Neurol 52:276-284,261, Hernan,M.A.,et al, 2002

Intakes of Vitamins E and C, Carotenoids, Vitamin Supplements, and PD Risk
Neurol 59:1161-1169, Zhang,S.M.,et al, 2002

T2-weighted MRI Differentiates Multiple System Atrophy from Parkinson's Disease
Neurol 59;1265-1267, Kraft,E.,et al, 2002

Clinicopath Conf., Sarcordosis with Hilar and Cervical Lymphadenopathy
NEJM 347:1350-1357, Case 33-2002, 2002

Familial Dementia With Lewy Bodies
Arch Neurol 59:1622-1630, Tsuang,D.W.,et al, 2002

Mitochondrial Therapy for Parkinson Disease
Arch Neurol 59:1523, Rosenberg,R.N., 2002

Clinicopath Conf., Lagerhans'-cell Histiocytosis
NEJM 346:513-520, Case 5-2002, 2002

Subthalamic DBS Replaces Levodopa in Parkinson's Disease
Neurol 58:396-401, Vingerhoets,F.J.G.,et al, 2002

Excessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson Disease
JAMA 287:455-463,509, Hobson,D.E.,et al, 2002

Practice Parameter: Initiation of Treatment for Parkinson's Disease: An Evidence-based Review
Neurol 58:11-17, Miyasaki,J.M.,et al, 2002

Cervical Disc Prolapse with Cord Compression Presenting with Choreoathetosis and Dystonia
Neurol 58:661-662, Tan,E.K.,et al, 2002

Diffusion-weighted MRI Differentiates the Parkinson Variant of Multiple System Atrophy from PD
Neurol 58:575-580, Schocke,M.F.H.,et al, 2002

Clinicopath Conf, Hyperviscosity Syndrome Due to IgG Multiple Myeloma
NEJM 346:603-610, Case 6-2002, 2002

Botulinum Toxin A Treatment for Primary Hemifacial Spasm
Arch Neurol 59:418-420, Defazio,G.,et al, 2002

Proton MR Spectroscopic Imaging Predicts Lesion Progression on MRI in X-Linked Adrenoleukodystrophy
Neurol 58:901-907, Eichler,F.S.,et al, 2002

Donepezil for Cognitive Impairment in Parkinson's Disease: A Randomised Controlled Study
JNNP 72:708-712, Aarsland,D.,et al, 2002